See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus
"Horisont 2020 programm" projekt MMVBS18281R
MMVBS18281R "Commercialising a novel glioblastoma targeted therapy and a companion diagnostic compound (1.06.2018−30.11.2019)", Tambet Teesalu, Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut.
SEP-210434716
MMVBS18281R
Commercialising a novel glioblastoma targeted therapy and a companion diagnostic compound
Commercialising a novel glioblastoma targeted therapy and a companion diagnostic compound
GLIOGUIDE
1.06.2018
30.11.2019
Teadus- ja arendusprojekt
Horisont 2020 programm
ValdkondAlamvaldkondCERCS erialaFrascati Manual’i erialaProtsent
3. Terviseuuringud3.1. BiomeditsiinB726 Kliiniline bioloogia 3.1 Biomeditsiin100,0
AsutusRiikTüüp
Euroopa Komisjon
PerioodSumma
01.06.2018−30.11.2019150 000,00 EUR
150 000,00 EUR

Glioblastoma (GBM), is the most aggressive form of primary brain cancer and is diagnosed in 22,000 people per year in the EU. GBM is the most aggressive primary brain cancer and, by annual incidence, the most common type of malignant brain tumour. Despite aggressive treatment, the cancer always recurs. The average survival after diagnosis is 12 to 15 months, with less than 3% to 5% of patients surviving longer than 5 years. Approximately 22,000 new cases are diagnosed in Europe annually. The current standard of care extends overall survival to ~14 -16 months. Current valuation of worldwide GBM treatment market is estimated to be €615 million per year, and it is predicted to increase to over €3.08 billion by 2024 (compound annual growth rate of 17%), based on the projected approval of new therapies including Opdivo and Optune. The main aim of this ERC PoC proposal is to probe the commercial viability of two types of tumour-targeted payload hybrids, one as an improved chemotherapeutic treatment, and the other as a precision-guided contrast agent for PET-based diagnosis and image-guided surgery. Our goal is for the former to become the clinician’s chemotherapy of choice in the adjuvant phase of GBM treatment; and for the latter to be incorporated into PET and MR-imaging procedures as a method for identifying and diagnosing GBM, as well as a companion test for stratification of patients for therapy.
Glioblastoma (GBM), is the most aggressive form of primary brain cancer and is diagnosed in 22,000 people per year in the EU. GBM is the most aggressive primary brain cancer and, by annual incidence, the most common type of malignant brain tumour. Despite aggressive treatment, the cancer always recurs. The average survival after diagnosis is 12 to 15 months, with less than 3% to 5% of patients surviving longer than 5 years. Approximately 22,000 new cases are diagnosed in Europe annually. The current standard of care extends overall survival to ~14 -16 months. Current valuation of worldwide GBM treatment market is estimated to be €615 million per year, and it is predicted to increase to over €3.08 billion by 2024 (compound annual growth rate of 17%), based on the projected approval of new therapies including Opdivo and Optune. The main aim of this ERC PoC proposal is to probe the commercial viability of two types of tumour-targeted payload hybrids, one as an improved chemotherapeutic treatment, and the other as a precision-guided contrast agent for PET-based diagnosis and image-guided surgery. Our goal is for the former to become the clinician’s chemotherapy of choice in the adjuvant phase of GBM treatment; and for the latter to be incorporated into PET and MR-imaging procedures as a method for identifying and diagnosing GBM, as well as a companion test for stratification of patients for therapy.
TegevusProtsent
Rakendusuuring50,0
Katse- ja arendustöö50,0